Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer
Kevin D. Courtney; Mary-Ellen Taplin(Profiled Author: Kevin D Courtney)
Current Opinion in Oncology. 2012;24(3):272-277.Abstract
Purpose of Review: The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent Findings: Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Summary: Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for patients with metastatic CRPC. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Kai-Hsiung Chang; Nima SharifiNature Reviews Urology. 2012;9(12):721-724.
Yingming Li; Siu Chiu Chan; Lucas J. Brand; Tae Hyun Hwang; Kevin A.T. Silverstein; Scott M. DehmCancer Research. 2013;73(2):483-489.
Nima SharifiExpert Opinion on Investigational Drugs. 2010;19(7):837-846.
Appears in this Document